Publications by authors named "Mirta Mosca"

Claim this Profile
C
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma.
Chiara Deiana, Andrea Palloni, Mirta Mosca, Francesco Vasuri, Stefano Chillotti

Front Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcome of Patients with Gastric, Duodenal, or Rectal Neuroendocrine Tumors after Incomplete Endoscopic Resection.
Elisabetta Dell'Unto, Matteo Marasco, Mirta Mosca, Camilla Gallo, Gianluca Esposito

J Clin Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond.
Mirta Mosca, Maria Concetta Nigro, Rachele Pagani, Andrea De Giglio, Alessandro Di Federico

Biomolecules· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
Mirta Mosca, Nicole Conci, Alessandro Di Federico, Valentina Tateo, Valentina Favorito

JCO Precis Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET).
Giuseppe Lamberti, Natalie Prinzi, Alberto Bongiovanni, Mariangela Torniai, Elisa Andrini, Mirta Mosca

Diagnostics (Basel)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory: a case report.
Mirta Mosca, Daria Maria Filippini, Nastassja Tober, Fabiola Lorena Rojas, Karim Rihawi

Anticancer Drugs· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-small-cell lung cancer: how to manage -positive disease.
Elisa Andrini, Mirta Mosca, Linda Galvani, Francesca Sperandi, Biagio Ricciuti

Drugs Context· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced non-small-cell lung cancer: how to manage and exon 20 insertion mutation-positive disease.
Giulio Metro, Andrea De Giglio, Biagio Ricciuti, Marco Siringo, Daniele Marinelli, Mirta Mosca

Drugs Context· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.
Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.
Vincenzo Di Nunno, Giacomo Nuvola, Mirta Mosca, Ilaria Maggio, Lidia Gatto

Immunotherapy· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
Alessandro Rizzo, Angela Dalia Ricci, Nastassja Tober, Maria Concetta Nigro, Mirta Mosca

Anticancer Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
Carlo Buonerba, Guru Sonpavde, Francesca Vitrone, Davide Bosso, Livio Puglia, Mirta Mosca

J Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis